DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
IPO Year: 2017
Exchange: NASDAQ
Website: dermtech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2022 | $48.00 | Outperform | Oppenheimer |
| 6/14/2022 | $38.00 → $19.00 | Buy | BTIG Research |
| 1/7/2022 | $26.00 | Overweight | Stephens |
| 1/7/2022 | Overweight | Stephens & Co. | |
| 10/15/2021 | $50.00 | Outperform | Cowen |
8-K - DermTech, Inc. (0001651944) (Filer)
8-K - DermTech, Inc. (0001651944) (Filer)
8-K - DermTech, Inc. (0001651944) (Filer)
8-K - DermTech, Inc. (0001651944) (Filer)
8-K - DermTech, Inc. (0001651944) (Filer)
10-K/A - DermTech, Inc. (0001651944) (Filer)
8-K - DermTech, Inc. (0001651944) (Filer)
8-K - DermTech, Inc. (0001651944) (Filer)
S-8 - DermTech, Inc. (0001651944) (Filer)
10-K - DermTech, Inc. (0001651944) (Filer)
4 - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
4/A - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
4 - DermTech, Inc. (0001651944) (Issuer)
Oppenheimer resumed coverage of DermTech with a rating of Outperform and set a new price target of $48.00
BTIG Research reiterated coverage of DermTech with a rating of Buy and set a new price target of $19.00 from $38.00 previously
Stephens initiated coverage of DermTech with a rating of Overweight and set a new price target of $26.00
Stephens & Co. initiated coverage of DermTech with a rating of Overweight
Cowen resumed coverage of DermTech with a rating of Outperform and set a new price target of $50.00
BTIG Research initiated coverage of DermTech with a rating of Buy and set a new price target of $53.00
Craig Hallum reiterated coverage of DermTech with a rating of Buy and set a new price target of $70.00 from $49.00 previously
Oppenheimer resumed coverage of DermTech with a rating of Buy and set a new price target of $58.00
Lake Street Capital reiterated coverage of DermTech with a rating of Buy and set a new price target of $79.00 from $52.00 previously
Oppenheimer initiated coverage of DermTech with a rating of Outperform and set a new price target of $53
SC 13G - DermTech, Inc. (0001651944) (Subject)
SC 13G/A - DermTech, Inc. (0001651944) (Subject)
SC 13D/A - DermTech, Inc. (0001651944) (Subject)
SC 13G/A - DermTech, Inc. (0001651944) (Subject)
SC 13G/A - DermTech, Inc. (0001651944) (Subject)
SC 13G/A - DermTech, Inc. (0001651944) (Subject)
SC 13D/A - DermTech, Inc. (0001651944) (Subject)
SC 13G/A - DermTech, Inc. (0001651944) (Subject)
SC 13G - DermTech, Inc. (0001651944) (Subject)
SC 13G/A - DermTech, Inc. (0001651944) (Subject)
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets. Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets. DermTech
- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus the first quarter of 2023 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue was $3.8 million, an 11 percent increase from
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in
DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effective March 27, 2024, the Compensation Committee of DermTech's Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan. The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously a DermTech employee, as inducements material to the employee's entering into employment with DermTech, in accordance with Nasdaq Listing Rule 5635(c)(4). The 26,2
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California. The first research abstract, "Non-invasive gene expression analyses to rule out melanoma in patients with Fitzpatrick skin types IV-VI" will be presented March 9th at 8:45am PT by Maral K. Skelsey, MD, lead author and Clinical Professor of Dermatology at Georgetown University's Medical School. In this research, the negative predictive value (NPV) for both Fitzpatrick skin t
- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year - Test revenue increased 38 percent versus the fourth quarter of 2022 - Estimated cash runway into the first quarter of 2025 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results. "We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024," said Bret Christensen, CEO, DermTech. "We've aligned our commer
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release. For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during
- Ongoing emphasis on growing revenue for the DermTech Melanoma Test (DMT) - Approximately $40 million in total operating expense reductions compared to fiscal 2022 resulting from all restructuring actions DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses. The Company has continued to rigorously evaluate its growth opportunities and operations, while dedicating substantially all of its resources to growing reimbursed DermTech Melanoma Test (DMT) bill
- Study demonstrated the DMT's effectiveness as a melanoma rule-out test for all skin types - Negative predictive value (NPV) higher than 99% regardless of skin type DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting. The peer-reviewed study entitled, "Non-invasive gene expression analysis rules out melanoma with high negative predictive value regardless of skin phototype" was presented at the W
- Trust 2 Study confirms negative predictive value (NPV) of 99.7% for the foundational gene expression assay - Optional TERT promoter mutation testing does not significantly alter sensitivity, NPV or positive predictive value (PPV) DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test (DMT) effective March 1, 2024. Multiple studies, including the Company's recently completed Trust 2 Study, demonstrated the DMT's negative predictive value (NPV) to be 99% or higher. A high NPV for
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in
- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year - Test revenue increased 38 percent versus the fourth quarter of 2022 - Estimated cash runway into the first quarter of 2025 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results. "We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024," said Bret Christensen, CEO, DermTech. "We've aligned our commer
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release. For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during
- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 8 percent versus the third quarter of 2022 - Cash runway into the first quarter of 2025 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its third-quarter 2023 financial results. "We're just a few months into our strategy of prioritizing reimbursed tests and growing revenue and are seeing faster progress than we expected," said Bret Christensen, CEO, DermTech. "We significantly improved many of our key performance indicators in the third quarter. We grew
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, November 2, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's third-quarter 2023 operating and financial results. In advance of the call on November 2, 2023, DermTech will issue its third-quarter 2023 earnings press release. For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during the
- Covered lives increased to 133 million - Average selling price and test revenue grew sequentially - Cash runway into the first quarter of 2025 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its second-quarter 2023 financial results. "We've recently taken a few necessary steps to streamline operations and put all our energy into scaling the DermTech Melanoma Test (DMT) and prioritizing reimbursed billable samples to grow revenue," said Bret Christensen, CEO, DermTech. "We're pursuing a large addressable market where significant patient need exists, with approximately 200,00
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, August 3, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's second-quarter 2023 operating and financial results. In advance of the call on August 3, 2023, DermTech will issue its second-quarter 2023 earnings press release. For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during the l
- Covered lives increased to 126 million - Cash runway through the third quarter of 2024 DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2023 financial results. "In the last few months, we had excellent overall progress with payers and strong execution by our commercial organization," said John Dobak, M.D., CEO, DermTech. "We expanded coverage for the DermTech Melanoma Test (DMT) by nearly 40 percent since the end of 2022. Payer momentum remains strong across a broad mix of large and medium-sized regional payers, governmental payers, self-funded employer allia
DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Thursday, May 4, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's first-quarter 2023 operating and financial results. In advance of the call on May 4, 2023, DermTech will issue its first-quarter 2023 earnings press release. For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during the live te
- Covered lives increased from 91 million to 124 million and cash runway through the third quarter of 2024 - Dr. John Dobak will continue to serve as CEO until a successor is appointed - Board initiates comprehensive CEO search DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its fourth-quarter and full-year 2022 financial results. The Company also announced that Dr. John Dobak expects to step away from his role as president, chief executive officer and director under a planned transition. "We're off to a great start in 2023, as we've grown covered lives from 91 million to 124 m
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech's overall commercial strategy and execution. Commenting on Mr. Aguillard's appointment, Bret Christensen, DermTech's CEO said, "I'd like to welcome Mark to the team. We are confident that his demonstrated success and wide breadth of commercial and payer access experience will serve us well during this transformational period as we focus on generating reimbursed tests to grow revenue. Mark's leadership will be i
DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Bret Christensen, previously chief commercial officer of Insulet, as president, chief executive officer and a member of the board of directors (the board). Mr. Christensen succeeds Dr. John Dobak, who stepped down as president, chief executive officer and a director of the board. Mr. Christensen said, "I am excited to be leading the DermTech team. DermTech has an opportunity to transform dermatology with its revolutionary technology, strong demand and building momentum with commercial payers. Importantly, I am co
DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, has appointed two new members to its senior leadership team. Jennifer Eilemberg has been named chief compliance officer and will oversee the Company's compliance with laws, regulatory requirements, rigorous internal policies and procedures. Steven Stone has stepped into the position of senior vice president of research and development and will guide the advancement of DermTech's non-invasive skin genomics platform and diverse product pipeline. "We are building an outstanding team of accomplished life science and healthcare leaders to steer the comp
DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company's board of directors, effective July 18,2022. These appointments expand DermTech's board of directors to eight members. "We are excited to welcome Kirk and Mark as new independent directors," commented Matt Posard, DermTech's chairman. "They are both accomplished life science executives, with an established track record in building companies, business development, capital formation and strategic partnerships. Their perspectives in guiding high-growth co
Former Ogilvy Regional CEO brings proven experience in creating iconic brands for Fortune 100 technology companies CasperLabs, a leading blockchain software company for the enterprise market, is pleased to announce that Michael Dobak has been appointed to the position of chief marketing officer. Mr. Dobak will have worldwide responsibility for the visibility, reputation and growth of the CasperLabs brand. Additionally, he is responsible for marketing initiatives targeting enterprise companies and the community of developers who are rapidly adopting blockchain. Mr. Dobak will report to Mrinal Manohar, CasperLabs co-founder and CEO, and will work in close partnership with the Casper Associat
DermTech, Inc. (NASDAQ:DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Nathalie Gerschtein Keraudy, President of the Consumer Products Division of L'Oréal, to its board of directors. "Nathalie has tremendous experience in building brands that consumers, clinicians, and the world recognize and trust," said Matt Posard, the Chairman of DermTech's board of directors. "Her unique and diverse perspectives will complement our efforts to make DermTech the trusted brand for genomic products that transform dermatologic care." Nathalie's experience includes 20 years at L'Oréal—the world's leading beauty compa
DermTech, Inc. (NASDAQ:DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Monica Tellado, Senior Vice President, Finance at Gilead Sciences to its Board of Directors. "We are so fortunate to welcome Monica to our Board of Directors," said Matt Posard, DermTech's Chairman of the Board. "As the company continues to scale for growth and expansion, Monica brings critical perspectives on commercializing new products and driving operational excellence to support business growth and efficiencies." Monica's experience includes 18 years at Gilead Sciences, in roles of progressive leadership responsibility up to
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Ray Akhavan to the role of General Counsel. Akhavan will serve on the executive leadership team and have responsibility for all legal, intellectual property and compliance matters. “Ray is the perfect fit for DermTech’s general counsel role given his balanced experience in medical and consumer genomics, and his foundation in science and intellectual property law,” commented John Dobak, M.D., CEO of DermTech. Akhavan has more than 16 years of experience that includes private practice a